SG10201710488TA - Delivery, Engineering and Optimization of Systems, Methods and Compositions for Targeting and Modeling Diseases and Disorders of Post Mitotic Cells - Google Patents
Delivery, Engineering and Optimization of Systems, Methods and Compositions for Targeting and Modeling Diseases and Disorders of Post Mitotic CellsInfo
- Publication number
- SG10201710488TA SG10201710488TA SG10201710488TA SG10201710488TA SG10201710488TA SG 10201710488T A SG10201710488T A SG 10201710488TA SG 10201710488T A SG10201710488T A SG 10201710488TA SG 10201710488T A SG10201710488T A SG 10201710488TA SG 10201710488T A SG10201710488T A SG 10201710488TA
- Authority
- SG
- Singapore
- Prior art keywords
- targeting
- disorders
- optimization
- engineering
- delivery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361836123P | 2013-06-17 | 2013-06-17 | |
US201361847537P | 2013-07-17 | 2013-07-17 | |
US201361862355P | 2013-08-05 | 2013-08-05 | |
US201361871301P | 2013-08-28 | 2013-08-28 | |
US201361915203P | 2013-12-12 | 2013-12-12 | |
PCT/US2013/074667 WO2014093622A2 (en) | 2012-12-12 | 2013-12-12 | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
US201461979573P | 2014-04-15 | 2014-04-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201710488TA true SG10201710488TA (en) | 2018-01-30 |
Family
ID=52105123
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201710488TA SG10201710488TA (en) | 2013-06-17 | 2014-06-11 | Delivery, Engineering and Optimization of Systems, Methods and Compositions for Targeting and Modeling Diseases and Disorders of Post Mitotic Cells |
SG11201510327TA SG11201510327TA (en) | 2013-06-17 | 2014-06-11 | Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201510327TA SG11201510327TA (en) | 2013-06-17 | 2014-06-11 | Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells |
Country Status (15)
Country | Link |
---|---|
US (1) | US20160153004A1 (en) |
EP (2) | EP3620524A1 (en) |
JP (2) | JP6738729B2 (en) |
KR (1) | KR20160019553A (en) |
CN (1) | CN105683379A (en) |
AU (1) | AU2014281030B2 (en) |
BR (1) | BR112015031611A2 (en) |
CA (1) | CA2915845A1 (en) |
DK (1) | DK3011032T3 (en) |
ES (1) | ES2767318T3 (en) |
IL (1) | IL243197B (en) |
MX (1) | MX2015017311A (en) |
RU (1) | RU2725502C2 (en) |
SG (2) | SG10201710488TA (en) |
WO (1) | WO2014204728A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
US11643652B2 (en) | 2019-03-19 | 2023-05-09 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11820969B2 (en) | 2016-12-23 | 2023-11-21 | President And Fellows Of Harvard College | Editing of CCR2 receptor gene to protect against HIV infection |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
US11920181B2 (en) | 2013-08-09 | 2024-03-05 | President And Fellows Of Harvard College | Nuclease profiling system |
US11932884B2 (en) | 2017-08-30 | 2024-03-19 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
Families Citing this family (226)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3613852A3 (en) | 2011-07-22 | 2020-04-22 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
EP3597741A1 (en) | 2012-04-27 | 2020-01-22 | Duke University | Genetic correction of mutated genes |
EA038924B1 (en) | 2012-05-25 | 2021-11-10 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
CN105441440B (en) | 2012-10-23 | 2020-12-15 | 基因工具股份有限公司 | Composition for cleaving target DNA comprising guide RNA specific for target DNA and CAS protein-encoding nucleic acid or CAS protein, and use thereof |
KR102531576B1 (en) | 2012-12-06 | 2023-05-11 | 시그마-알드리치 컴퍼니., 엘엘씨 | Crispr-based genome modification and regulation |
ES2701749T3 (en) | 2012-12-12 | 2019-02-25 | Broad Inst Inc | Methods, models, systems and apparatus to identify target sequences for Cas enzymes or CRISPR-Cas systems for target sequences and transmit results thereof |
ES2883590T3 (en) | 2012-12-12 | 2021-12-09 | Broad Inst Inc | Supply, modification and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
LT3456831T (en) | 2013-04-16 | 2021-09-10 | Regeneron Pharmaceuticals, Inc. | Targeted modification of rat genome |
KR20230136697A (en) * | 2013-06-05 | 2023-09-26 | 듀크 유니버시티 | Rna-guided gene editing and gene regulation |
CA2915834A1 (en) | 2013-06-17 | 2014-12-24 | Massachusetts Institute Of Technology | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
EP3725885A1 (en) | 2013-06-17 | 2020-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
CN105492611A (en) | 2013-06-17 | 2016-04-13 | 布罗德研究所有限公司 | Optimized CRISPR-CAS double nickase systems, methods and compositions for sequence manipulation |
CN105793425B (en) | 2013-06-17 | 2021-10-26 | 布罗德研究所有限公司 | Delivery, use and therapeutic applications of CRISPR-CAS systems and compositions for targeting disorders and diseases using viral components |
RU2716420C2 (en) | 2013-06-17 | 2020-03-11 | Те Брод Инститьют Инк. | Delivery and use of systems of crispr-cas, vectors and compositions for targeted action and therapy in liver |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
WO2015040402A1 (en) | 2013-09-18 | 2015-03-26 | Kymab Limited | Methods. cells & organisms |
DK3066201T3 (en) | 2013-11-07 | 2018-06-06 | Editas Medicine Inc | CRISPR-RELATED PROCEDURES AND COMPOSITIONS WITH LEADING GRADES |
WO2015088643A1 (en) | 2013-12-11 | 2015-06-18 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
US20150166982A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting pi3k point mutations |
AU2014361781B2 (en) | 2013-12-12 | 2021-04-01 | Massachusetts Institute Of Technology | Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing |
WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
JP6712948B2 (en) | 2013-12-12 | 2020-06-24 | ザ・ブロード・インスティテュート・インコーポレイテッド | Compositions and methods of using the CRISPR-cas system in nucleotide repeat disorders |
WO2015089486A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems |
AU2015222944A1 (en) | 2014-02-27 | 2016-09-08 | Massachusetts Institute Of Technology | T cell balance gene expression, compositions of matters and methods of use thereof |
WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
WO2016028682A1 (en) | 2014-08-17 | 2016-02-25 | The Broad Institute Inc. | Genome editing using cas9 nickases |
WO2016049163A2 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder |
WO2016049251A1 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes |
WO2016049258A2 (en) | 2014-09-25 | 2016-03-31 | The Broad Institute Inc. | Functional screening with optimized functional crispr-cas systems |
EP3561052A1 (en) | 2014-10-15 | 2019-10-30 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for generating or maintaining pluripotent cells |
US20170247762A1 (en) | 2014-10-27 | 2017-08-31 | The Board Institute Inc. | Compositions, methods and use of synthetic lethal screening |
JP6788584B2 (en) * | 2014-10-31 | 2020-11-25 | マサチューセッツ インスティテュート オブ テクノロジー | Massively Parallel Combinatorial Genetics on CRISPR |
WO2016073990A2 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
RS58893B1 (en) | 2014-11-21 | 2019-08-30 | Regeneron Pharma | Methods and compositions for targeted genetic modification using paired guide rnas |
US11168369B2 (en) | 2014-11-25 | 2021-11-09 | The Brigham And Women's Hospital, Inc. | Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease |
CN107250148B (en) | 2014-12-03 | 2021-04-16 | 安捷伦科技有限公司 | Guide RNAs with chemical modifications |
US9888673B2 (en) | 2014-12-10 | 2018-02-13 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
EP3230452A1 (en) | 2014-12-12 | 2017-10-18 | The Broad Institute Inc. | Dead guides for crispr transcription factors |
WO2016094874A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Escorted and functionalized guides for crispr-cas systems |
WO2016094880A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs) |
EP3985115A1 (en) | 2014-12-12 | 2022-04-20 | The Broad Institute, Inc. | Protected guide rnas (pgrnas) |
WO2016100974A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing |
WO2016106236A1 (en) | 2014-12-23 | 2016-06-30 | The Broad Institute Inc. | Rna-targeting system |
WO2016106244A1 (en) | 2014-12-24 | 2016-06-30 | The Broad Institute Inc. | Crispr having or associated with destabilization domains |
WO2016108926A1 (en) | 2014-12-30 | 2016-07-07 | The Broad Institute Inc. | Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis |
JP6929791B2 (en) | 2015-02-09 | 2021-09-01 | デューク ユニバーシティ | Compositions and methods for epigenome editing |
WO2016138488A2 (en) | 2015-02-26 | 2016-09-01 | The Broad Institute Inc. | T cell balance gene expression, compositions of matters and methods of use thereof |
GB2536650A (en) | 2015-03-24 | 2016-09-28 | Augmedics Ltd | Method and system for combining video-based and optic-based augmented reality in a near eye display |
WO2016161380A1 (en) * | 2015-04-01 | 2016-10-06 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy and becker muscular dystrophy |
KR102648489B1 (en) | 2015-04-06 | 2024-03-15 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Chemically modified guide RNA for CRISPR/CAS-mediated gene regulation |
WO2016182893A1 (en) | 2015-05-08 | 2016-11-17 | Teh Broad Institute Inc. | Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof |
AU2016261358B2 (en) | 2015-05-11 | 2021-09-16 | Editas Medicine, Inc. | Optimized CRISPR/Cas9 systems and methods for gene editing in stem cells |
AU2016276702B2 (en) | 2015-06-09 | 2022-07-28 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for improving transplantation |
WO2016205728A1 (en) | 2015-06-17 | 2016-12-22 | Massachusetts Institute Of Technology | Crispr mediated recording of cellular events |
FI3430134T3 (en) | 2015-06-18 | 2023-01-13 | Novel crispr enzymes and systems | |
WO2016205745A2 (en) * | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Cell sorting |
CN108290933A (en) | 2015-06-18 | 2018-07-17 | 布罗德研究所有限公司 | Reduce the CRISPR enzyme mutants of undershooting-effect |
WO2016205749A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
WO2016205759A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation |
CN106282118A (en) * | 2015-06-24 | 2017-01-04 | 武汉荣实医药科技有限公司 | The genetically engineered cell strain of alzheimer's disease key pathogenetic factor app and medicaments sifting model |
JP2018519811A (en) | 2015-06-29 | 2018-07-26 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | Modified CRISPR RNA and modified single CRISPR RNA and uses thereof |
EP3325018A4 (en) | 2015-07-22 | 2019-04-24 | Duke University | High-throughput screening of regulatory element function with epigenome editing technologies |
WO2017023803A1 (en) | 2015-07-31 | 2017-02-09 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
WO2017031232A1 (en) * | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
WO2017031370A1 (en) | 2015-08-18 | 2017-02-23 | The Broad Institute, Inc. | Methods and compositions for altering function and structure of chromatin loops and/or domains |
CA2996001A1 (en) * | 2015-08-25 | 2017-03-02 | Duke University | Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases |
EP3353298B1 (en) * | 2015-09-21 | 2023-09-13 | Arcturus Therapeutics, Inc. | Allele selective gene editing and uses thereof |
EP3786294A1 (en) | 2015-09-24 | 2021-03-03 | Editas Medicine, Inc. | Use of exonucleases to improve crispr/cas-mediated genome editing |
US20190255107A1 (en) | 2015-10-09 | 2019-08-22 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
EP4089175A1 (en) | 2015-10-13 | 2022-11-16 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
CA3024543A1 (en) | 2015-10-22 | 2017-04-27 | The Broad Institute, Inc. | Type vi-b crispr enzymes and systems |
JP7109784B2 (en) | 2015-10-23 | 2022-08-01 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Evolved Cas9 protein for gene editing |
EP3368687B1 (en) | 2015-10-27 | 2021-09-29 | The Broad Institute, Inc. | Compositions and methods for targeting cancer-specific sequence variations |
EP3368689B1 (en) | 2015-10-28 | 2020-06-17 | The Broad Institute, Inc. | Composition for modulating immune responses by use of immune cell gene signature |
WO2017075265A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute, Inc. | Multiplex analysis of single cell constituents |
WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
WO2017075294A1 (en) | 2015-10-28 | 2017-05-04 | The Board Institute Inc. | Assays for massively combinatorial perturbation profiling and cellular circuit reconstruction |
WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
CA3005878A1 (en) | 2015-11-19 | 2017-05-26 | The Brigham And Women's Hospital, Inc. | Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity |
WO2017114497A1 (en) | 2015-12-30 | 2017-07-06 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
EA201891619A1 (en) | 2016-01-11 | 2019-02-28 | Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити | CHEMERAL PROTEINS AND METHODS OF REGULATING GENE EXPRESSION |
JP7012645B2 (en) | 2016-01-11 | 2022-01-28 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Chimeric proteins and immunotherapeutic methods |
WO2017147196A1 (en) | 2016-02-22 | 2017-08-31 | Massachusetts Institute Of Technology | Methods for identifying and modulating immune phenotypes |
EP3219799A1 (en) | 2016-03-17 | 2017-09-20 | IMBA-Institut für Molekulare Biotechnologie GmbH | Conditional crispr sgrna expression |
WO2017161325A1 (en) | 2016-03-17 | 2017-09-21 | Massachusetts Institute Of Technology | Methods for identifying and modulating co-occurant cellular phenotypes |
US20190218276A1 (en) * | 2016-03-21 | 2019-07-18 | The Broad Institute, Inc. | Methods for determining spatial and temporal gene expression dynamics in single cells |
US11597924B2 (en) | 2016-03-25 | 2023-03-07 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
WO2017180694A1 (en) | 2016-04-13 | 2017-10-19 | Editas Medicine, Inc. | Cas9 fusion molecules gene editing systems, and methods of use thereof |
EP4166660A1 (en) | 2016-04-29 | 2023-04-19 | BASF Plant Science Company GmbH | Improved methods for modification of target nucleic acids using fused guide rna - donor molecules |
US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
EP3455357A1 (en) | 2016-06-17 | 2019-03-20 | The Broad Institute Inc. | Type vi crispr orthologs and systems |
WO2017223128A1 (en) | 2016-06-21 | 2017-12-28 | The Curators Of The University Of Missouri | Modified dystrophin proteins |
CN106047877B (en) * | 2016-06-24 | 2019-01-11 | 中山大学附属第一医院 | A kind of sgRNA and CRISPR/Cas9 slow virus system of targeting knockout FTO gene and application |
US20180004537A1 (en) | 2016-07-01 | 2018-01-04 | Microsoft Technology Licensing, Llc | Molecular State Machines |
CN109477130B (en) * | 2016-07-01 | 2022-08-30 | 微软技术许可有限责任公司 | Storage by iterative DNA editing |
US11359234B2 (en) | 2016-07-01 | 2022-06-14 | Microsoft Technology Licensing, Llc | Barcoding sequences for identification of gene expression |
US11124805B2 (en) | 2016-07-13 | 2021-09-21 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
KR101961332B1 (en) * | 2016-07-28 | 2019-03-22 | 기초과학연구원 | Pharmaceutical Composition for Treating or Preventing Eye Disease Comprising Cas9 Protein and Guide RNA |
US11608570B2 (en) * | 2016-07-29 | 2023-03-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Targeted in situ protein diversification by site directed DNA cleavage and repair |
WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
WO2018031762A1 (en) * | 2016-08-10 | 2018-02-15 | Duke University | Compositions, systems and methods for programming immune cell function through targeted gene regulation |
KR101710026B1 (en) * | 2016-08-10 | 2017-02-27 | 주식회사 무진메디 | Composition comprising delivery carrier of nano-liposome having Cas9 protein and guide RNA |
WO2018035250A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Methods for identifying class 2 crispr-cas systems |
US11630103B2 (en) | 2016-08-17 | 2023-04-18 | The Broad Institute, Inc. | Product and methods useful for modulating and evaluating immune responses |
WO2018035388A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
WO2018049025A2 (en) | 2016-09-07 | 2018-03-15 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses |
WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2018071868A1 (en) | 2016-10-14 | 2018-04-19 | President And Fellows Of Harvard College | Aav delivery of nucleobase editors |
WO2018071663A1 (en) * | 2016-10-14 | 2018-04-19 | Emendobio Inc. | Rna compositions for genome editing |
GB2573406B (en) | 2016-10-18 | 2021-11-10 | Univ Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
WO2018083606A1 (en) | 2016-11-01 | 2018-05-11 | Novartis Ag | Methods and compositions for enhancing gene editing |
CN108220339A (en) * | 2016-12-14 | 2018-06-29 | 深圳华大生命科学研究院 | The method of cell transformation |
KR101796036B1 (en) * | 2016-12-29 | 2017-11-10 | 주식회사 무진메디 | Delivery carrier composition comprising nanoliposome encapsulating complex of Cas9 protein, guide RNA for repressing gene expression or KRAS gene and cationic polymer, or therapeutics comprising thereof for treating KRAS mutation colon cancer with anticancer drug resistance |
CN108265068B (en) * | 2016-12-31 | 2021-06-15 | 江苏众红生物工程创药研究院有限公司 | Recombinant arginine deiminase and industrial preparation method and application thereof |
MX2019008675A (en) | 2017-01-23 | 2019-09-18 | Regeneron Pharma | Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof. |
TW201839136A (en) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | Compositions and methods for the treatment of hemoglobinopathies |
JP2020508056A (en) * | 2017-02-22 | 2020-03-19 | クリスパー・セラピューティクス・アクチェンゲゼルシャフトCRISPR Therapeutics AG | Compositions and methods for gene editing |
KR102185464B1 (en) | 2017-03-15 | 2020-12-03 | 매사추세츠 인스티튜트 오브 테크놀로지 | New CAS13B Ortholog CRISPR Enzyme and System |
US20200115753A1 (en) | 2017-03-17 | 2020-04-16 | Massachusetts Institute Of Technology | Methods for identifying and modulating co-occurant cellular phenotypes |
CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
WO2018183908A1 (en) | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
US11913075B2 (en) | 2017-04-01 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
AU2018250727A1 (en) | 2017-04-11 | 2019-10-31 | Regeneron Pharmaceuticals, Inc. | Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (HSD17B) family |
WO2018191388A1 (en) | 2017-04-12 | 2018-10-18 | The Broad Institute, Inc. | Novel type vi crispr orthologs and systems |
EP3610266A4 (en) | 2017-04-12 | 2021-04-21 | Massachusetts Eye and Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
WO2018191520A1 (en) | 2017-04-12 | 2018-10-18 | The Broad Institute, Inc. | Respiratory and sweat gland ionocytes |
US20200405639A1 (en) | 2017-04-14 | 2020-12-31 | The Broad Institute, Inc. | Novel delivery of large payloads |
MX2019012398A (en) | 2017-04-18 | 2020-09-25 | Broad Inst Inc | Compositions for detecting secretion and methods of use. |
EP3612232A1 (en) | 2017-04-21 | 2020-02-26 | The Broad Institute, Inc. | Targeted delivery to beta cells |
EP3615672A1 (en) | 2017-04-28 | 2020-03-04 | Editas Medicine, Inc. | Methods and systems for analyzing guide rna molecules |
WO2018204777A2 (en) | 2017-05-05 | 2018-11-08 | The Broad Institute, Inc. | Methods for identification and modification of lncrna associated with target genotypes and phenotypes |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
AU2018270088A1 (en) | 2017-05-18 | 2020-01-16 | Massachusetts Institute Of Technology | Systems, methods, and compositions for targeted nucleic acid editing |
US11603544B2 (en) | 2017-06-05 | 2023-03-14 | Fred Hutchinson Cancer Center | Genomic safe harbors for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies |
CN110997908A (en) | 2017-06-09 | 2020-04-10 | 爱迪塔斯医药公司 | Engineered CAS9 nucleases |
EP3638218A4 (en) | 2017-06-14 | 2021-06-09 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
CN111032867A (en) * | 2017-06-16 | 2020-04-17 | 应用干细胞有限公司 | Gene editing method with improved typing efficiency |
CN111328290A (en) | 2017-06-26 | 2020-06-23 | 博德研究所 | CRISPR/CAS-adenine deaminase-based compositions, systems, and methods for targeted nucleic acid editing |
US20200140896A1 (en) | 2017-06-30 | 2020-05-07 | Novartis Ag | Methods for the treatment of disease with gene editing systems |
EP3645021A4 (en) | 2017-06-30 | 2021-04-21 | Intima Bioscience, Inc. | Adeno-associated viral vectors for gene therapy |
EP3652312A1 (en) | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
JP2020533957A (en) | 2017-07-31 | 2020-11-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | CRISPR Reporter Non-Human Animals and Their Use |
MX2020001178A (en) | 2017-07-31 | 2020-09-25 | Regeneron Pharma | Cas-transgenic mouse embryonic stem cells and mice and uses thereof. |
AU2018338318B2 (en) | 2017-09-21 | 2022-12-22 | Massachusetts Institute Of Technology | Systems, methods, and compositions for targeted nucleic acid editing |
EP3688161A1 (en) | 2017-09-29 | 2020-08-05 | Intellia Therapeutics, Inc. | Compositions and methods for ttr gene editing and treating attr amyloidosis |
US20200255828A1 (en) | 2017-10-04 | 2020-08-13 | The Broad Institute, Inc. | Methods and compositions for altering function and structure of chromatin loops and/or domains |
CA3078883A1 (en) | 2017-10-11 | 2019-04-18 | Regeneron Pharmaceuticals, Inc. | Inhibition of hsd17b13 in the treatment of liver disease in patients expressing the pnpla3 i148m variation |
CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
US11680296B2 (en) | 2017-10-16 | 2023-06-20 | Massachusetts Institute Of Technology | Mycobacterium tuberculosis host-pathogen interaction |
KR20200085781A (en) | 2017-10-20 | 2020-07-15 | 프레드 헛친슨 켄서 리서치 센터 | Systems and methods for producing B cells genetically modified to express selected antibodies |
US11547614B2 (en) | 2017-10-31 | 2023-01-10 | The Broad Institute, Inc. | Methods and compositions for studying cell evolution |
EP3704245A1 (en) | 2017-11-01 | 2020-09-09 | Novartis AG | Synthetic rnas and methods of use |
US11332736B2 (en) | 2017-12-07 | 2022-05-17 | The Broad Institute, Inc. | Methods and compositions for multiplexing single cell and single nuclei sequencing |
CN109971755B (en) * | 2017-12-27 | 2024-03-01 | 信立泰(成都)生物技术有限公司 | Tumor-targeted gene therapy drug based on CRISPR/Cas9 gene editing technology and application thereof |
KR20200109358A (en) | 2018-01-17 | 2020-09-22 | 버텍스 파마슈티칼스 인코포레이티드 | DNA-PK inhibitor |
WO2019143678A1 (en) | 2018-01-17 | 2019-07-25 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
CN108265036B (en) * | 2018-01-26 | 2021-04-27 | 山东大学齐鲁医院 | T1 protein silencing recombinant virus and construction method and application thereof |
CA3089331A1 (en) | 2018-03-19 | 2019-09-26 | Regeneron Pharmaceuticals, Inc. | Transcription modulation in animals using crispr/cas systems |
EP3781711A4 (en) | 2018-04-19 | 2022-01-26 | Massachusetts Institute Of Technology | Single-stranded break detection in double-stranded dna |
SI3560330T1 (en) | 2018-04-24 | 2022-08-31 | KWS SAAT SE & Co. KGaA | Plants with improved digestibility and marker haplotypes |
US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
US20210147831A1 (en) | 2018-04-27 | 2021-05-20 | The Broad Institute, Inc. | Sequencing-based proteomics |
WO2019210491A1 (en) * | 2018-05-03 | 2019-11-07 | 深圳市博奥康生物科技有限公司 | Crispr/cas9 targeted knockout of human cvap gene and specific grna thereof |
WO2019213660A2 (en) | 2018-05-04 | 2019-11-07 | The Broad Institute, Inc. | Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses |
CN108588050B (en) * | 2018-05-14 | 2021-06-25 | 北京艾克伦医疗科技有限公司 | DNA polymerase, and nucleic acid detection method and kit |
US20210371932A1 (en) | 2018-06-01 | 2021-12-02 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
BR112020025319A2 (en) | 2018-06-26 | 2021-03-09 | The Broad Institute Inc. | COMPOSITIONS, SYSTEMS AND METHODS OF AMPLIFICATION BASED ON CRISPR / CAS AND TRANSPOSASE |
EP3814527B1 (en) | 2018-06-26 | 2023-02-22 | Massachusetts Institute of Technology | Crispr effector system based amplification methods, systems, and diagnostics |
EP3830256A2 (en) | 2018-07-31 | 2021-06-09 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
JP2021532815A (en) | 2018-08-07 | 2021-12-02 | ザ・ブロード・インスティテュート・インコーポレイテッド | New Cas12b enzyme and system |
US20210317429A1 (en) | 2018-08-20 | 2021-10-14 | The Broad Institute, Inc. | Methods and compositions for optochemical control of crispr-cas9 |
US20210324357A1 (en) | 2018-08-20 | 2021-10-21 | The Brigham And Women's Hospital, Inc. | Degradation domain modifications for spatio-temporal control of rna-guided nucleases |
WO2020051507A1 (en) | 2018-09-06 | 2020-03-12 | The Broad Institute, Inc. | Nucleic acid assemblies for use in targeted delivery |
EP4268831A2 (en) | 2018-09-12 | 2023-11-01 | Fred Hutchinson Cancer Center | Reducing cd33 expression to selectively protect therapeutic cells |
JP7344300B2 (en) | 2018-09-18 | 2023-09-13 | ブイエヌブイ ニューコ インク. | ARC-based capsids and their uses |
WO2020077236A1 (en) | 2018-10-12 | 2020-04-16 | The Broad Institute, Inc. | Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues |
US20210379057A1 (en) | 2018-10-16 | 2021-12-09 | Massachusetts Institute Of Technology | Nutlin-3a for use in treating a mycobacterium tuberculosis infection |
US11766296B2 (en) | 2018-11-26 | 2023-09-26 | Augmedics Ltd. | Tracking system for image-guided surgery |
AU2019406778A1 (en) | 2018-12-17 | 2021-07-22 | Massachusetts Institute Of Technology | Crispr-associated transposase systems and methods of use thereof |
WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
CA3124395A1 (en) | 2018-12-20 | 2020-06-25 | Basf Plant Science Company Gmbh | Native delivery of biomolecules into plant cells using ionic complexes with cell-penetrating peptides |
US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
SG11202109073VA (en) * | 2019-02-20 | 2021-09-29 | Rubius Therapeutics Inc | Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use |
US20220162649A1 (en) | 2019-04-01 | 2022-05-26 | The Broad Institute, Inc. | Novel nucleic acid modifiers |
CN110057610B (en) * | 2019-04-25 | 2021-09-07 | 上海联影医疗科技股份有限公司 | Vibration information determination method and device, medical imaging equipment and storage medium |
EP3969607A1 (en) | 2019-05-13 | 2022-03-23 | KWS SAAT SE & Co. KGaA | Drought tolerance in corn |
US20220220469A1 (en) | 2019-05-20 | 2022-07-14 | The Broad Institute, Inc. | Non-class i multi-component nucleic acid targeting systems |
WO2020236967A1 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Random crispr-cas deletion mutant |
AR118995A1 (en) | 2019-05-25 | 2021-11-17 | Kws Saat Se & Co Kgaa | HAPLOID INDUCTION ENHANCER |
US20220243178A1 (en) | 2019-05-31 | 2022-08-04 | The Broad Institute, Inc. | Methods for treating metabolic disorders by targeting adcy5 |
EP3801011A1 (en) | 2019-06-04 | 2021-04-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
SG11202111943UA (en) | 2019-07-02 | 2021-11-29 | Hutchinson Fred Cancer Res | Recombinant ad35 vectors and related gene therapy improvements |
EP3772542A1 (en) | 2019-08-07 | 2021-02-10 | KWS SAAT SE & Co. KGaA | Modifying genetic variation in crops by modulating the pachytene checkpoint protein 2 |
WO2021041922A1 (en) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
CA3151563A1 (en) | 2019-09-20 | 2021-03-25 | Feng Zhang | Novel type vi crispr enzymes and systems |
WO2021057932A1 (en) * | 2019-09-26 | 2021-04-01 | 上海原能细胞医学技术有限公司 | Modified immune cell and use thereof |
AU2020366566A1 (en) | 2019-10-17 | 2022-04-21 | KWS SAAT SE & Co. KGaA | Enhanced disease resistance of crops by downregulation of repressor genes |
JP2023503899A (en) | 2019-11-22 | 2023-02-01 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Ionic liquids for drug delivery |
CN114945273A (en) | 2019-11-29 | 2022-08-26 | 巴斯夫欧洲公司 | Increasing the resistance of plants against fungal infections |
AU2020408995A1 (en) | 2019-12-16 | 2022-06-23 | BASF Agricultural Solutions Seed US LLC | Codon-optimized Cas9 endonuclease encoding polynucleotide |
CA3161898A1 (en) | 2019-12-19 | 2021-06-24 | Basf Se | Increasing space-time-yield, carbon-conversion-efficiency and carbon substrate flexibility in the production of fine chemicals |
EP4077658A1 (en) | 2019-12-20 | 2022-10-26 | Basf Se | Decreasing toxicity of terpenes and increasing the production potential in micro-organisms |
US11382712B2 (en) | 2019-12-22 | 2022-07-12 | Augmedics Ltd. | Mirroring in image guided surgery |
EP3872190A1 (en) | 2020-02-26 | 2021-09-01 | Antibodies-Online GmbH | A method of using cut&run or cut&tag to validate crispr-cas targeting |
WO2021175759A1 (en) | 2020-03-04 | 2021-09-10 | Basf Se | Method for the production of constitutive bacterial promoters conferring low to medium expression |
WO2021175756A1 (en) | 2020-03-04 | 2021-09-10 | Basf Se | Shuttle vector for expression in e. coli and bacilli |
CN111700034B (en) * | 2020-05-22 | 2021-12-14 | 中国人民解放军空军军医大学 | Construction method and application of schizophrenia animal model based on central nervous system myelin sheath function change |
CN116782762A (en) | 2020-05-29 | 2023-09-19 | 科沃施种子欧洲股份两合公司 | Plant haploid induction |
WO2022074056A2 (en) | 2020-10-07 | 2022-04-14 | Basf Se | Bacillus cell with reduced lipase and/or esterase side activities |
EP4001429A1 (en) | 2020-11-16 | 2022-05-25 | Antibodies-Online GmbH | Analysis of crispr-cas binding and cleavage sites followed by high-throughput sequencing (abc-seq) |
CN112941075B (en) * | 2021-02-02 | 2023-02-10 | 同济大学 | Method for constructing double-phenotype rat model of thyroid dysfunction and heart long QT syndrome |
GB202101958D0 (en) * | 2021-02-12 | 2021-03-31 | Ucl Business Ltd | Gene therapy for dopamine transporter deficiency syndrome |
EP4359546A1 (en) | 2021-06-24 | 2024-05-01 | Basf Se | Improved bacillus host cell with altered rema/remb protein |
EP4359423A1 (en) | 2021-06-24 | 2024-05-01 | Basf Se | Bacillus licheniformis host cell for production of a compound of interest with increased purity |
US11896445B2 (en) | 2021-07-07 | 2024-02-13 | Augmedics Ltd. | Iliac pin and adapter |
AR126622A1 (en) | 2021-07-30 | 2023-10-25 | Kws Saat Se & Co Kgaa | PLANTS WITH IMPROVED DIGESTIBILITY AND MARKER HAPLOTYPES |
AU2022343300A1 (en) | 2021-09-10 | 2024-04-18 | Agilent Technologies, Inc. | Guide rnas with chemical modification for prime editing |
CA3233824A1 (en) | 2021-10-08 | 2023-04-13 | Samir Mitragotri | Ionic liquids for drug delivery |
CN114121148B (en) * | 2021-11-11 | 2023-01-06 | 苏州大学 | Method for calculating protein-ligand binding free energy based on cluster model |
WO2023093862A1 (en) | 2021-11-26 | 2023-06-01 | Epigenic Therapeutics Inc. | Method of modulating pcsk9 and uses thereof |
WO2023117970A1 (en) | 2021-12-20 | 2023-06-29 | Basf Se | Method for improved production of intracellular proteins in bacillus |
WO2024042199A1 (en) | 2022-08-26 | 2024-02-29 | KWS SAAT SE & Co. KGaA | Use of paired genes in hybrid breeding |
Family Cites Families (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11029A (en) | 1854-06-06 | Improvement in seed-planters | ||
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
DE122007000007I1 (en) | 1986-04-09 | 2007-05-16 | Genzyme Corp | Genetically transformed animals secreting a desired protein in milk |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
WO1991017424A1 (en) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
US7745416B2 (en) * | 1995-04-11 | 2010-06-29 | The Regents Of The University Of California | Method for in vivo regulation of cardiac muscle contractility |
EP0831854A4 (en) | 1995-06-06 | 2001-01-24 | Isis Pharmaceuticals Inc | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5985662A (en) | 1995-07-13 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of hepatitis B virus replication |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5846946A (en) | 1996-06-14 | 1998-12-08 | Pasteur Merieux Serums Et Vaccins | Compositions and methods for administering Borrelia DNA |
GB9907461D0 (en) | 1999-03-31 | 1999-05-26 | King S College London | Neurite regeneration |
GB9720465D0 (en) | 1997-09-25 | 1997-11-26 | Oxford Biomedica Ltd | Dual-virus vectors |
WO1999021977A1 (en) | 1997-10-24 | 1999-05-06 | Life Technologies, Inc. | Recombinational cloning using nucleic acids having recombination sites |
US6750059B1 (en) | 1998-07-16 | 2004-06-15 | Whatman, Inc. | Archiving of vectors |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6479808B1 (en) | 1999-07-07 | 2002-11-12 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Method and systems for collecting data from multiple fields of view |
GB0024550D0 (en) | 2000-10-06 | 2000-11-22 | Oxford Biomedica Ltd | |
WO2003014318A2 (en) * | 2001-08-08 | 2003-02-20 | Genzyme Corporation | Methods for treating diabetes and other blood sugar disorders |
AU2002336760A1 (en) | 2001-09-26 | 2003-06-10 | Mayo Foundation For Medical Education And Research | Mutable vaccines |
GB0125216D0 (en) | 2001-10-19 | 2001-12-12 | Univ Strathclyde | Dendrimers for use in targeted delivery |
AU2002353231B2 (en) | 2001-12-21 | 2008-10-16 | Oxford Biomedica (Uk) Limited | Method for producing a transgenic organism using a lentiviral expression vector such as EIAV |
US7206639B2 (en) | 2002-03-15 | 2007-04-17 | Sarcos Investments Lc | Cochlear drug delivery system and method |
JP2006513694A (en) * | 2002-06-11 | 2006-04-27 | ザ スクリップス リサーチ インスティテュート | Artificial transcription factor |
US7867193B2 (en) | 2004-01-29 | 2011-01-11 | The Charles Stark Draper Laboratory, Inc. | Drug delivery apparatus |
WO2004002453A1 (en) | 2002-06-28 | 2004-01-08 | Protiva Biotherapeutics Ltd. | Method and apparatus for producing liposomes |
GB0220467D0 (en) | 2002-09-03 | 2002-10-09 | Oxford Biomedica Ltd | Composition |
WO2004046321A2 (en) * | 2002-11-15 | 2004-06-03 | Trustees Of Boston University | Cis/trans riboregulators |
US20060178297A1 (en) * | 2003-01-28 | 2006-08-10 | Troy Carol M | Systems and methods for silencing expression of a gene in a cell and uses thereof |
AU2004257373B2 (en) | 2003-07-16 | 2011-03-24 | Arbutus Biopharma Corporation | Lipid encapsulated interfering RNA |
NZ592917A (en) | 2003-09-15 | 2012-12-21 | Protiva Biotherapeutics Inc | Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates |
GB0325379D0 (en) | 2003-10-30 | 2003-12-03 | Oxford Biomedica Ltd | Vectors |
US8673634B2 (en) | 2003-11-13 | 2014-03-18 | Massachusetts Eye & Ear Infirmary | Method for the treatment of hearing loss |
ATE536418T1 (en) | 2004-06-07 | 2011-12-15 | Protiva Biotherapeutics Inc | LIPID ENCAPSULATED INTERFERENCE RNA |
EP1781593B1 (en) | 2004-06-07 | 2011-12-14 | Protiva Biotherapeutics Inc. | Cationic lipids and methods of use |
FR2872170B1 (en) * | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | NON-INTERACTIVE AND NON-REPLICATIVE LENTIVIRUS, PREPARATION AND USES |
CA2573702C (en) | 2004-07-16 | 2013-10-15 | The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services | Vaccine constructs and combination of vaccines designed to improve the breadth of the immune response to diverse strains and clades of hiv |
GB0422877D0 (en) | 2004-10-14 | 2004-11-17 | Univ Glasgow | Bioactive polymers |
PL2325332T3 (en) * | 2005-08-26 | 2013-03-29 | Dupont Nutrition Biosci Aps | Use of CRISPR associated genes (CAS) |
US9265933B2 (en) | 2005-09-08 | 2016-02-23 | Massachusetts Eye And Ear Infirmary | Cochlear implants containing biological cells and uses thereof |
WO2007048046A2 (en) | 2005-10-20 | 2007-04-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of filovirus gene expression |
EP1948674A4 (en) | 2005-11-02 | 2009-02-04 | Protiva Biotherapeutics Inc | Modified sirna molecules and uses thereof |
GB0526211D0 (en) | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
WO2007093836A1 (en) | 2006-02-13 | 2007-08-23 | Cellectis | Meganuclease variants cleaving a dna target sequence from a xp gene and uses thereof |
CN103614375A (en) * | 2006-05-11 | 2014-03-05 | 阿尔尼拉姆医药品有限公司 | Composition and method for inhibiting expression of PCSK9 gene |
US7915399B2 (en) | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
WO2008010009A1 (en) | 2006-07-18 | 2008-01-24 | Cellectis | Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof |
JP2008078613A (en) | 2006-08-24 | 2008-04-03 | Rohm Co Ltd | Method of producing nitride semiconductor, and nitride semiconductor element |
US20100146651A1 (en) | 2006-11-14 | 2010-06-10 | Cellectis | Meganuclease variants cleaving a dna target sequence from the hprt gene and uses thereof |
PE20090064A1 (en) * | 2007-03-26 | 2009-03-02 | Novartis Ag | DOUBLE-CHAIN RIBONUCLEIC ACID TO INHIBIT THE EXPRESSION OF THE HUMAN E6AP GENE AND THE PHARMACEUTICAL COMPOSITION THAT INCLUDES IT |
WO2008149176A1 (en) | 2007-06-06 | 2008-12-11 | Cellectis | Meganuclease variants cleaving a dna target sequence from the mouse rosa26 locus and uses thereof |
WO2009013559A1 (en) | 2007-07-23 | 2009-01-29 | Cellectis | Meganuclease variants cleaving a dna target sequence from the human hemoglobin beta gene and uses thereof |
WO2009019528A1 (en) | 2007-08-03 | 2009-02-12 | Cellectis | Meganuclease variants cleaving a dna target sequence from the human interleukin-2 receptor gamma chain gene and uses thereof |
CN101801445B (en) | 2007-08-14 | 2013-04-17 | 弗雷德哈钦森癌症研究中心 | Needle array assembly for delivering therapeutic agents |
AU2008346801A1 (en) | 2007-12-31 | 2009-07-16 | Nanocor Therapeutics, Inc. | RNA interference for the treatment of heart failure |
CN101990433B (en) | 2008-02-07 | 2014-11-05 | 马萨诸塞眼科耳科诊所 | Compounds that enhance atoh-1 expression |
US20100081707A1 (en) * | 2008-02-21 | 2010-04-01 | Ali Robin R | Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea |
AU2009238175C1 (en) | 2008-04-15 | 2023-11-30 | Arbutus Biopharma Corporation | Novel lipid formulations for nucleic acid delivery |
WO2009147368A1 (en) | 2008-06-04 | 2009-12-10 | Medical Research Council | Peptides |
WO2009147684A2 (en) | 2008-06-06 | 2009-12-10 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
AU2009265170A1 (en) | 2008-06-30 | 2010-01-07 | Silenseed Ltd | Methods, compositions and systems for local delivery of drugs |
US20110117189A1 (en) | 2008-07-08 | 2011-05-19 | S.I.F.I. Societa' Industria Farmaceutica Italiana S.P.A. | Ophthalmic compositions for treating pathologies of the posterior segment of the eye |
WO2010014218A2 (en) | 2008-07-29 | 2010-02-04 | Academia Sinica | Puf-a and related compounds for treatment of retinopathies and sight-threatening ophthalmologic disorders |
WO2010026443A1 (en) | 2008-09-08 | 2010-03-11 | Cellectis | Meganuclease variants cleaving a dna target sequence from a glutamine synthetase gene and uses thereof |
MX2011002731A (en) | 2008-09-15 | 2011-04-26 | Childrens Medical Center | Modulation of bcl11a for treatment of hemoglobinopathies. |
US20100076057A1 (en) * | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
WO2010053518A2 (en) | 2008-10-29 | 2010-05-14 | Sangamo Biosciences, Inc. | Methods and compositions for inactivating glutamine synthetase gene expression |
JP6087504B2 (en) | 2008-11-07 | 2017-03-01 | マサチューセッツ インスティテュート オブ テクノロジー | Amino alcohol lipidoids and uses thereof |
US20110023139A1 (en) | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in cardiovascular disease |
US20120159653A1 (en) | 2008-12-04 | 2012-06-21 | Sigma-Aldrich Co. | Genomic editing of genes involved in macular degeneration |
US20110023146A1 (en) | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in secretase-associated disorders |
US20110023145A1 (en) | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in autism spectrum disorders |
US20110016540A1 (en) | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Genome editing of genes associated with trinucleotide repeat expansion disorders in animals |
US20110023153A1 (en) | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in alzheimer's disease |
US20110023144A1 (en) | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in amyotrophyic lateral sclerosis disease |
AU2009324534B2 (en) * | 2008-12-10 | 2015-07-30 | Alnylam Pharmaceuticals, Inc. | GNAQ targeted dsRNA compositions and methods for inhibiting expression |
JP5932632B2 (en) | 2009-03-20 | 2016-06-15 | サンガモ バイオサイエンシーズ, インコーポレイテッド | Modification of CXCR4 using modified zinc finger protein |
WO2010129602A2 (en) | 2009-05-04 | 2010-11-11 | Fred Hutchinson Cancer Research Center | Cocal vesiculovirus envelope pseudotyped retroviral vectors |
CA2767127A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
EP2449106B1 (en) | 2009-07-01 | 2015-04-08 | Protiva Biotherapeutics Inc. | Compositions and methods for silencing apolipoprotein b |
WO2011016840A2 (en) * | 2009-07-28 | 2011-02-10 | Sangamo Biosciences, Inc. | Methods and compositions for treating trinucleotide repeat disorders |
US8927807B2 (en) | 2009-09-03 | 2015-01-06 | The Regents Of The University Of California | Nitrate-responsive promoter |
US8889394B2 (en) | 2009-09-07 | 2014-11-18 | Empire Technology Development Llc | Multiple domain proteins |
US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
US8771985B2 (en) | 2010-04-26 | 2014-07-08 | Sangamo Biosciences, Inc. | Genome editing of a Rosa locus using zinc-finger nucleases |
WO2011141820A1 (en) | 2010-05-12 | 2011-11-17 | Cellectis | Meganuclease variants cleaving a dna target sequence from the dystrophin gene and uses thereof |
EP2569435A1 (en) | 2010-05-12 | 2013-03-20 | Cellectis | Meganuclease variants cleaving a dna target sequence from the rhodopsin gene and uses thereof |
US8372951B2 (en) | 2010-05-14 | 2013-02-12 | National Tsing Hua University | Cell penetrating peptides for intracellular delivery |
ES2536791T3 (en) | 2010-05-28 | 2015-05-28 | Oxford Biomedica (Uk) Ltd | Administration of lentiviral vectors to the brain |
EP2609135A4 (en) | 2010-08-26 | 2015-05-20 | Massachusetts Inst Technology | Poly(beta-amino alcohols), their preparation, and uses thereof |
US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
WO2012106725A2 (en) | 2011-02-04 | 2012-08-09 | Sangamo Biosciences, Inc. | Methods and compositions for treating occular disorders |
PL2691443T3 (en) | 2011-03-28 | 2021-08-30 | Massachusetts Institute Of Technology | Conjugated lipomers and uses thereof |
EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US20120295960A1 (en) | 2011-05-20 | 2012-11-22 | Oxford Biomedica (Uk) Ltd. | Treatment regimen for parkinson's disease |
WO2013044008A2 (en) * | 2011-09-21 | 2013-03-28 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of transgene expression |
WO2013052681A1 (en) | 2011-10-06 | 2013-04-11 | Sangamo Biosciences, Inc. | Methods and compositions for regulating hiv infection |
AU2012328682B2 (en) | 2011-10-27 | 2017-09-21 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of the HPRT locus |
JP6348064B2 (en) * | 2011-11-22 | 2018-06-27 | ザ チルドレンズ ホスピタル オブ フィラデルフィア | Viral vectors for efficient transgene delivery |
US8450107B1 (en) * | 2011-11-30 | 2013-05-28 | The Broad Institute Inc. | Nucleotide-specific recognition sequences for designer TAL effectors |
KR20140102759A (en) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | Modified nucleoside, nucleotide, and nucleic acid compositions |
DK2836226T3 (en) | 2012-02-24 | 2017-09-18 | Hutchinson Fred Cancer Res | COMPOSITIONS AND PROCEDURES FOR TREATING HEMOGLOBINOPATHY |
CA2865011C (en) | 2012-02-29 | 2021-06-15 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
EP3597741A1 (en) | 2012-04-27 | 2020-01-22 | Duke University | Genetic correction of mutated genes |
EA038924B1 (en) * | 2012-05-25 | 2021-11-10 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
KR102531576B1 (en) * | 2012-12-06 | 2023-05-11 | 시그마-알드리치 컴퍼니., 엘엘씨 | Crispr-based genome modification and regulation |
CA2910489A1 (en) * | 2013-05-15 | 2014-11-20 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a genetic condition |
WO2014191518A1 (en) * | 2013-05-29 | 2014-12-04 | Cellectis | A method for producing precise dna cleavage using cas9 nickase activity |
RU2716420C2 (en) * | 2013-06-17 | 2020-03-11 | Те Брод Инститьют Инк. | Delivery and use of systems of crispr-cas, vectors and compositions for targeted action and therapy in liver |
-
2014
- 2014-06-11 RU RU2016101178A patent/RU2725502C2/en active
- 2014-06-11 SG SG10201710488TA patent/SG10201710488TA/en unknown
- 2014-06-11 SG SG11201510327TA patent/SG11201510327TA/en unknown
- 2014-06-11 EP EP19171576.2A patent/EP3620524A1/en not_active Withdrawn
- 2014-06-11 KR KR1020167001039A patent/KR20160019553A/en not_active Application Discontinuation
- 2014-06-11 MX MX2015017311A patent/MX2015017311A/en active IP Right Grant
- 2014-06-11 EP EP14735795.8A patent/EP3011032B1/en not_active Revoked
- 2014-06-11 CN CN201480045708.7A patent/CN105683379A/en active Pending
- 2014-06-11 BR BR112015031611A patent/BR112015031611A2/en not_active Application Discontinuation
- 2014-06-11 WO PCT/US2014/041808 patent/WO2014204728A1/en active Application Filing
- 2014-06-11 CA CA2915845A patent/CA2915845A1/en not_active Abandoned
- 2014-06-11 DK DK14735795.8T patent/DK3011032T3/en active
- 2014-06-11 ES ES14735795T patent/ES2767318T3/en active Active
- 2014-06-11 JP JP2016521452A patent/JP6738729B2/en active Active
- 2014-06-11 AU AU2014281030A patent/AU2014281030B2/en active Active
-
2015
- 2015-12-16 US US14/971,169 patent/US20160153004A1/en active Pending
- 2015-12-17 IL IL243197A patent/IL243197B/en active IP Right Grant
-
2019
- 2019-09-24 JP JP2019172824A patent/JP2020063238A/en active Pending
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11920181B2 (en) | 2013-08-09 | 2024-03-05 | President And Fellows Of Harvard College | Nuclease profiling system |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11820969B2 (en) | 2016-12-23 | 2023-11-21 | President And Fellows Of Harvard College | Editing of CCR2 receptor gene to protect against HIV infection |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11932884B2 (en) | 2017-08-30 | 2024-03-19 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11643652B2 (en) | 2019-03-19 | 2023-05-09 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11795452B2 (en) | 2019-03-19 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
Also Published As
Publication number | Publication date |
---|---|
WO2014204728A1 (en) | 2014-12-24 |
EP3011032A1 (en) | 2016-04-27 |
BR112015031611A2 (en) | 2017-12-12 |
EP3011032B1 (en) | 2019-10-16 |
JP2020063238A (en) | 2020-04-23 |
MX2015017311A (en) | 2017-04-10 |
RU2725502C2 (en) | 2020-07-02 |
KR20160019553A (en) | 2016-02-19 |
CA2915845A1 (en) | 2014-12-24 |
RU2016101178A3 (en) | 2019-04-08 |
AU2014281030B2 (en) | 2020-07-09 |
RU2016101178A (en) | 2018-11-19 |
DK3011032T3 (en) | 2020-01-20 |
US20160153004A1 (en) | 2016-06-02 |
SG11201510327TA (en) | 2016-01-28 |
JP2016523082A (en) | 2016-08-08 |
ES2767318T3 (en) | 2020-06-17 |
CN105683379A (en) | 2016-06-15 |
JP6738729B2 (en) | 2020-08-12 |
EP3620524A1 (en) | 2020-03-11 |
IL243197A0 (en) | 2016-03-31 |
IL243197B (en) | 2020-08-31 |
WO2014204728A8 (en) | 2015-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL243197A0 (en) | Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells | |
AU2014281030A1 (en) | Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells | |
IL272423A (en) | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components | |
HK1252619A1 (en) | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications | |
HK1218935A1 (en) | Systems and methods for the targeted production of a therapeutic protein within a target cell | |
IL252755A0 (en) | Methods and compositions for targeted genetic modification through single-step multiple targeting | |
HK1223646A1 (en) | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation | |
ZA201506682B (en) | Compositions and methods for the improved production and delivery of rna | |
HK1219719A1 (en) | Compositions and methods for delivering messenger rna | |
IL243195A0 (en) | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components | |
EP2958574A4 (en) | Compositions and methods for genetic analysis of embryos | |
EP2972216A4 (en) | Beam shaping optics of flow cytometer systems and methods related thereto | |
ZA201406698B (en) | Genetic reduction of male fertility in plants | |
IL284102A (en) | Marker for acid sphingomyelinase disorders and uses thereof | |
EP2971288A4 (en) | Compositions, methods, and computer systems related to making and administering modified t cells | |
EP3011336A4 (en) | Methods, systems, and composition related to neural disorders | |
AU2013900448A0 (en) | Delivery System for administering small particles to humans | |
GB201301385D0 (en) | Particle structures for drug delivery | |
AU2013900369A0 (en) | Computer-implemented system for influencing commuter behaviour |